Neutropenia Clinical Trial
OBJECTIVES: I. Determine the efficacy of bone marrow transplantation using matched related
donors in patients with nonmalignant hematologic disorders.
II. Determine the quality of life, absence of adverse effects (e.g., graft versus host
disease and B cell lymphoproliferative disease), and completeness of recovery of their
underlying condition in these patients with this treatment regimen.
PROTOCOL OUTLINE: Patients receive IV or oral busulfan every 6 hours on days -9 to -6;
cyclophosphamide IV on days -5 to -2; anti-thymocyte globulin IV on days -4 to -2; and
allogeneic bone marrow transplantation (BMT) on day 0.
Patients with class 3 thalassemia (liver edge greater than 2 cm below costal margin, a
history of inconsistent chelation, and portal fibrosis) receive a less intensive
conditioning regimen consisting of oral busulfan every 6 hours on days -7 to -4;
anti-thymocyte globulin IV on days -5 to -1 and days 1-5; cyclophosphamide IV on days -3 to
-2; and allogeneic BMT on day 0.
Patients are followed at day 28, and then at 3, 6, 12, and 24 months.
;
Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02452034 -
Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)
|
Phase 1 | |
| Not yet recruiting |
NCT02806557 -
Profiling Neutrophil Counts in Patients on Chemotherapy
|
N/A | |
| Not yet recruiting |
NCT01714557 -
Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation
|
N/A | |
| Completed |
NCT01371656 -
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
|
Phase 3 | |
| Active, not recruiting |
NCT00020865 -
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
|
Phase 3 | |
| Completed |
NCT00257790 -
The Tobramycin Study
|
Phase 4 | |
| Completed |
NCT00020371 -
BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy
|
Phase 1 | |
| Terminated |
NCT00005787 -
Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma
|
Phase 1 | |
| Completed |
NCT00001533 -
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine
|
Phase 1 | |
| Completed |
NCT05585463 -
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
|
||
| Not yet recruiting |
NCT02238873 -
Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma
|
Phase 3 | |
| Completed |
NCT01058993 -
AMD 3100 for Treatment of Myelokathexis
|
Phase 1 | |
| Completed |
NCT00771810 -
Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer
|
Phase 2 | |
| Completed |
NCT00770172 -
G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy
|
Phase 3 | |
| Completed |
NCT00771433 -
G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer
|
Phase 2 | |
| Terminated |
NCT00529282 -
A Study of Ceftobiprole in Patients With Fever and Neutropenia.
|
Phase 3 | |
| Active, not recruiting |
NCT00030758 -
Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer
|
Phase 4 | |
| Completed |
NCT00001790 -
Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia
|
Phase 1 | |
| Completed |
NCT00002693 -
Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia
|
Phase 1 | |
| Active, not recruiting |
NCT04154488 -
A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders
|
Phase 1/Phase 2 |